$5.60
3.70% yesterday
Nasdaq, Aug 12, 10:09 pm CET
ISIN
US0396971071
Symbol
ARDX

Ardelyx, Inc. Stock price

$5.60
+0.99 21.48% 1M
+0.15 2.75% 6M
+0.53 10.45% YTD
-0.22 3.78% 1Y
+4.67 502.80% 3Y
-0.13 2.27% 5Y
-12.65 69.32% 10Y
-8.51 60.31% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.20 3.70%
ISIN
US0396971071
Symbol
ARDX
Industry

Key metrics

Basic
Market capitalization
$1.3b
Enterprise Value
$1.3b
Net debt
positive
Cash
$238.5m
Shares outstanding
240.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.4 | 3.5
EV/Sales
3.3 | 3.4
EV/FCF
negative
P/B
9.3
Financial Health
Equity Ratio
39.8%
Return on Equity
-22.6%
ROCE
-10.5%
ROIC
-20.5%
Debt/Equity
1.4
Financials (TTM | estimate)
Revenue
$386.2m | $367.3m
EBITDA
$-38.1m | $-57.1m
EBIT
$-40.4m | $-84.3m
Net Income
$-56.4m | $-99.0m
Free Cash Flow
$-55.2m
Growth (TTM | estimate)
Revenue
83.9% | 10.1%
EBITDA
33.5% | -120.7%
EBIT
31.4% | -201.5%
Net Income
13.4% | -153.0%
Free Cash Flow
35.7%
Margin (TTM | estimate)
Gross
84.8%
EBITDA
-9.9% | -15.6%
EBIT
-10.5%
Net
-14.6% | -27.0%
Free Cash Flow
-14.3%
More
EPS
$-0.2
FCF per Share
$-0.2
Short interest
13.1%
Employees
395
Rev per Employee
$840.0k
Show more

Is Ardelyx, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Ardelyx, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Ardelyx, Inc. forecast:

16x Buy
89%
2x Hold
11%

Analyst Opinions

18 Analysts have issued a Ardelyx, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Ardelyx, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
386 386
84% 84%
100%
- Direct Costs 59 59
100% 100%
15%
327 327
81% 81%
85%
- Selling and Administrative Expenses 308 308
56% 56%
80%
- Research and Development Expense 60 60
44% 44%
15%
-38 -38
33% 33%
-10%
- Depreciation and Amortization 2.29 2.29
38% 38%
1%
EBIT (Operating Income) EBIT -40 -40
31% 31%
-10%
Net Profit -56 -56
13% 13%
-15%

In millions USD.

Don't miss a Thing! We will send you all news about Ardelyx, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ardelyx, Inc. Stock News

Positive
The Motley Fool
7 days ago
Ardelyx Q2 Revenue Jumps 33%
Neutral
Seeking Alpha
8 days ago
Ardelyx, Inc. (NASDAQ:ARDX ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Eric Duane Foster - Chief Commercial Officer Justin A. Renz - Chief Financial & Operations Officer Michael G.
Neutral
GlobeNewsWire
8 days ago
Edward Conner, M.D. appointed Chief Medical Officer and John Bishop, Ph.D.
More Ardelyx, Inc. News

Company Profile

Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

Head office United States
CEO Mike Raab
Employees 395
Founded 2007
Website www.ardelyx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today